U.S. announces pharmaceutical tariffs under Section 232: what it means for biotech compani... 10/04/2026 Healthcare Drug discovery Rare diseases Innovative drugs Industrial biotechnology International At AseBio, we believe this Executive Order creates uncertainty for the European biotechnology sector—especially for... AseBio
Biobide obtains two ENAC GLP certifications and expands its capacity to conduct studies fo... 07/04/2026 Healthcare Climate change Agrifood Industrial biotechnology International Corporate Biobide, a subsidiary of Biotechnology Assets (BME Growth: BST), has obtained two Good Laboratory Practice (GLP)... Partners - Biotechnology Assets
BCN HEALTH publishes a systematic review highlighting the substantial economic burden of h... 01/04/2026 Healthcare Access to innovation BCN HEALTH has published the study “Economic burden of heart failure in Europe: A systematic review of costs and cost... Partners - BCN Health
Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation 27/03/2026 Healthcare Drug discovery InceptionBio is a new €100 million target-size fund focused on biotech company creation and early-stage projects, with a... Partners - Ysios Capital Partners
Josep Samitier: "It's key to strengthen public private collaboration and attract venture ... 27/03/2026 Healthcare Industrial biotechnology Josep Samitier, a leading figure in bioengineering and nanomedicine, reflects on the key milestones of his time at the... Partners - GENESIS Biomed
ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance 25/03/2026 Healthcare Innovative drugs Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD). Partners - Oryzon Genomics
Aptadel Therapeutics raises 2 million euros and prepares a new round to bring the projec... 24/03/2026 Healthcare Drug discovery Aptadel Therapeutics advances in its treatment for Ewing's sarcoma after closing a bridge round of 2 million euros. Partners - Parc Científic de Barcelona
MTBVAC moves toward its final stage: the vaccine candidate that could mark a turning point... 24/03/2026 Healthcare Innovative drugs According to WHO and ECDC data, 161,569 cases were reported in 2024 across 51 of the 53 countries in the European region... AseBio - Zendal
MTBVAC moves toward its final stage: the vaccine candidate that could mark a turning point... 24/03/2026 Zendal According to WHO and ECDC data, 161,569 cases were reported in 2024 across 51 of the 53 countries in the European region... AseBio - Zendal
ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax 23/03/2026 Healthcare Drug discovery Innovative drugs Recent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in... Partners - Oryzon Genomics
